BioXcel Therapeutics Provides Clinical and Business Update

Core Insights - BioXcel Therapeutics is advancing its SERENITY and TRANQUILITY clinical programs aimed at treating acute agitation associated with bipolar disorders, schizophrenia, and Alzheimer's dementia, addressing an estimated 140 million annual agitation episodes [2][6] - The company has enhanced its operational and financial flexibility through an amendment to its existing credit agreement and successfully raised $7 million in equity funding [7] - Recent appointments to the Board of Directors have strengthened the company's leadership with expertise in clinical, financial, and legal areas [5][8] Clinical Programs - The SERENITY At-Home Phase 3 trial for BXCL501 is progressing with patient enrollment, focusing on acute treatment for agitation related to bipolar disorders and schizophrenia [1][6] - Plans for the TRANQUILITY In-Care Phase 3 trial of BXCL501 for agitation associated with Alzheimer's dementia have been developed [1][6] Financial and Operational Updates - The company has improved its financial position by amending its credit agreement, which was announced on November 25, 2024 [7] - The recent equity funding raised$7 million in gross proceeds, which closed on the same date [7] Leadership Enhancements - The Board of Directors has been strengthened with new members who bring significant operational and clinical expertise, including Dr. Rajiv Patni and David Mack [5][8] - Dr. Rajiv Patni has extensive experience in global product development across various therapeutic areas [5] - David Mack has over 25 years of experience in financial and legal leadership, aiding companies through transitions [8]